All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
PHI terminates agreement regarding liquidity provider
PHI today announces that the Company has terminated the liquidity provider agreement with Pareto Securities AB. The agreement will expire on July 31, 2024.
PostNews

BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
PostNews: Press Release
PHI secures a loan facility of in total SEK 7 million
PHI announces that the Company has secured a loan facility of in total SEK 7 million from Bizcap AB, and from that loan facility decided to draw a tranche of SEK 4.5 million.
PostNews: Press Release

PHI announces conference schedule for spring 2024
PHI is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in select industry webinars and events.
PostNews: Interim Report

Interim Report 3 2023/24
This quarter set new records for PHI, achieving our highest-ever sales and advancing our strategic initiatives significantly. The strengthening of our partnership with Altium and the expanding reach of QPI technology highlights our leading position in the field. This quarter truly shows our continuous progress toward our core mission: making cell-based therapies accessible, affordable, and safe for all.
PostNews

BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.

New CEO commentary — “Redefining aging with HoloMonitor”
In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.
New CEO commentary: “The scientific role of commercialization”
On PHI’s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”, see CEO commentary The scientific role of commercialization, published February 18, 2018.

Life is a mess
In our daily lives, we all know how important it is to plan ahead to avoid a future mess. Ironically, we ourselves are such a future mess.

Fighting cancer with nanoparticles
Using HoloMonitor, scientists at Northeastern University have shown that paclitaxel-resistant ovarian cancer cells stopped multiplying by cell division when treated with nanoparticles. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.